UTAH MEDICAL PRODUCTS, INC. Revenue
UTAH MEDICAL PRODUCTS, INC. (UTMD) reported Revenue of $8.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- UTAH MEDICAL PRODUCTS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $8.53M, a 14.31% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $8.72M, a 10.18% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $9.04M, a 1.23% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $9.81M, a 1.93% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $38.52M, a 5.83% decline from fiscal 2024.
- UTAH MEDICAL PRODUCTS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $40.90M, a 18.56% decline from fiscal 2023.
- UTAH MEDICAL PRODUCTS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $50.22M, a 3.93% decline from fiscal 2022.
- UTAH MEDICAL PRODUCTS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $52.28M, a 6.58% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.53M 10-Q · filed 2026-08-12 | $17.25M 10-Q · filed 2026-08-12 | $26.30M derived: sum of 3 quarters · filed 2026-08-12 | $36.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $8.72M 10-Q · filed 2026-05-12 | $17.77M derived: sum of 2 quarters · filed 2026-05-12 | $27.58M derived: sum of 3 quarters · filed 2026-05-12 | $37.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $9.04M 10-K · filed 2026-03-27 | $18.86M derived: sum of 2 quarters · filed 2026-03-27 | $28.81M derived: sum of 3 quarters · filed 2026-08-12 | $38.52M 10-K · filed 2026-03-27 |
| 2025-09-30 | $9.81M 10-K · filed 2026-03-27 | $19.77M derived: sum of 2 quarters · filed 2026-08-12 | $29.48M 10-Q · filed 2025-11-14 | $38.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $9.95M 10-Q · filed 2026-08-12 | $19.66M 10-Q · filed 2026-08-12 | $28.82M derived: sum of 3 quarters · filed 2026-08-12 | $38.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $9.71M 10-Q · filed 2026-05-12 | $18.87M derived: sum of 2 quarters · filed 2026-05-12 | $28.87M derived: sum of 3 quarters · filed 2026-05-12 | $39.27M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $9.16M 10-K · filed 2026-03-27 | $19.16M derived: sum of 2 quarters · filed 2026-03-27 | $29.56M derived: sum of 3 quarters · filed 2026-03-27 | $40.90M 10-K · filed 2026-03-27 |
| 2024-09-30 | $10.01M 10-K · filed 2026-03-27 | $20.41M derived: sum of 2 quarters · filed 2026-03-27 | $31.75M 10-Q · filed 2025-11-14 | $44.08M derived: sum of 4 quarters · filed 2026-03-27 |
| 2024-06-30 | $10.40M 10-K · filed 2026-03-27 | $21.74M 10-Q · filed 2025-08-12 | $34.07M derived: sum of 3 quarters · filed 2026-03-27 | $46.58M derived: sum of 4 quarters · filed 2026-03-27 |
| 2024-03-31 | $11.34M 10-K · filed 2026-03-27 | $23.67M derived: sum of 2 quarters · filed 2026-03-27 | $36.18M derived: sum of 3 quarters · filed 2026-03-27 | $49.04M derived: sum of 4 quarters · filed 2026-03-27 |
| 2023-12-31 | $12.33M 10-K · filed 2026-03-27 | $24.84M derived: sum of 2 quarters · filed 2026-03-27 | $37.70M derived: sum of 3 quarters · filed 2026-03-27 | $50.22M 10-K · filed 2026-03-27 |
| 2023-09-30 | $12.51M 10-K · filed 2026-03-27 | $25.37M derived: sum of 2 quarters · filed 2026-03-27 | $37.89M 10-Q · filed 2024-11-12 | $51.47M derived: sum of 4 quarters · filed 2026-03-27 |
| 2023-06-30 | $12.87M 10-K · filed 2026-03-27 | $25.39M 10-Q · filed 2024-08-09 | $38.96M derived: sum of 3 quarters · filed 2026-03-27 | $51.92M derived: sum of 4 quarters · filed 2026-03-27 |
| 2023-03-31 | $12.52M 10-K · filed 2026-03-27 | $26.09M derived: sum of 2 quarters · filed 2026-03-27 | $39.05M derived: sum of 3 quarters · filed 2026-03-27 | $52.48M derived: sum of 4 quarters · filed 2026-03-27 |
| 2022-12-31 | $13.57M 10-K · filed 2025-03-26 | $26.53M derived: sum of 2 quarters · filed 2025-03-26 | $39.96M derived: sum of 3 quarters · filed 2025-03-26 | $52.28M 10-K · filed 2025-03-26 |
| 2022-09-30 | $12.96M 10-K · filed 2025-03-26 | $26.38M derived: sum of 2 quarters · filed 2025-03-26 | $38.71M 10-Q · filed 2023-11-13 | $51.62M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-06-30 | $13.43M 10-K · filed 2025-03-26 | $25.75M 10-Q · filed 2023-08-11 | $38.66M derived: sum of 3 quarters · filed 2025-03-26 | $51.24M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-03-31 | $12.32M 10-K · filed 2025-03-26 | $25.24M derived: sum of 2 quarters · filed 2025-03-26 | $37.81M derived: sum of 3 quarters · filed 2025-03-26 | $50.41M derived: sum of 4 quarters · filed 2025-03-26 |
| 2021-12-31 | $12.91M 10-K · filed 2024-03-26 | $25.49M derived: sum of 2 quarters · filed 2024-03-26 | $38.09M derived: sum of 3 quarters · filed 2024-03-26 | $49.05M 10-K · filed 2024-03-26 |
| 2021-09-30 | $12.57M 10-K · filed 2024-03-26 | $25.18M derived: sum of 2 quarters · filed 2024-03-26 | $36.14M 10-Q · filed 2022-11-10 | $48.15M derived: sum of 4 quarters · filed 2024-03-26 |
| 2021-06-30 | $12.60M 10-K · filed 2024-03-26 | $23.57M 10-Q · filed 2022-08-12 | $35.58M derived: sum of 3 quarters · filed 2024-03-26 | $46.06M derived: sum of 4 quarters · filed 2024-03-26 |
| 2021-03-31 | $10.96M 10-K · filed 2024-03-26 | $22.97M derived: sum of 2 quarters · filed 2024-03-26 | $33.45M derived: sum of 3 quarters · filed 2024-03-26 | $42.24M derived: sum of 4 quarters · filed 2024-03-26 |
| 2020-12-31 | $12.01M 10-K/A · filed 2023-03-28 | $22.49M derived: sum of 2 quarters · filed 2023-03-28 | $31.28M derived: sum of 3 quarters · filed 2023-03-28 | $42.18M 10-K/A · filed 2023-03-28 |
| 2020-09-30 | $10.48M 10-K/A · filed 2023-03-28 | $19.27M derived: sum of 2 quarters · filed 2023-03-28 | $30.17M 10-Q · filed 2021-11-12 | $42.00M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-06-30 | $8.79M 10-K/A · filed 2023-03-28 | $19.69M 10-Q · filed 2021-08-06 | $31.52M derived: sum of 3 quarters · filed 2023-03-28 | $44.01M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-03-31 | $10.90M 10-K/A · filed 2023-03-28 | $22.73M derived: sum of 2 quarters · filed 2023-03-28 | $35.23M derived: sum of 3 quarters · filed 2023-03-28 | $47.07M derived: sum of 4 quarters · filed 2023-03-28 |
| 2019-12-31 | $11.83M 10-K · filed 2022-03-25 | $24.32M derived: sum of 2 quarters · filed 2022-03-25 | $36.17M derived: sum of 3 quarters · filed 2022-03-25 | $46.90M 10-K · filed 2022-03-25 |
| 2019-09-30 | $12.49M 10-K · filed 2022-03-25 | $24.34M derived: sum of 2 quarters · filed 2022-03-25 | $35.07M 10-Q/A · filed 2020-11-09 | $44.83M derived: sum of 4 quarters · filed 2022-03-25 |
| 2019-06-30 | $11.85M 10-K · filed 2022-03-25 | $22.58M 10-Q · filed 2020-08-07 | $32.33M derived: sum of 3 quarters · filed 2022-03-25 | $42.72M derived: sum of 4 quarters · filed 2022-03-25 |
| 2019-03-31 | $10.73M 10-K · filed 2022-03-25 | $20.49M derived: sum of 2 quarters · filed 2022-03-25 | $30.88M derived: sum of 3 quarters · filed 2022-03-25 | $41.84M derived: sum of 4 quarters · filed 2022-03-25 |
| 2018-12-31 | $9.76M 10-K · filed 2021-03-26 | $20.15M derived: sum of 2 quarters · filed 2021-03-26 | $31.11M derived: sum of 3 quarters · filed 2021-03-26 | $42.00M 10-K · filed 2021-03-26 |
| 2018-09-30 | $10.39M 10-K · filed 2021-03-26 | $21.36M derived: sum of 2 quarters · filed 2021-03-26 | $32.24M 10-Q · filed 2019-11-07 | $42.44M derived: sum of 4 quarters · filed 2021-03-26 |
| 2018-06-30 | $10.96M 10-K · filed 2021-03-26 | $21.85M 10-Q · filed 2019-08-09 | $32.05M derived: sum of 3 quarters · filed 2021-03-26 | $42.18M derived: sum of 4 quarters · filed 2021-03-26 |
| 2018-03-31 | $10.89M 10-K · filed 2021-03-26 | $21.09M derived: sum of 2 quarters · filed 2021-03-26 | $31.21M derived: sum of 3 quarters · filed 2021-03-26 | $42.04M derived: sum of 4 quarters · filed 2021-03-26 |
| 2017-12-31 | $10.20M 10-K · filed 2020-03-16 | $20.33M derived: sum of 2 quarters · filed 2020-03-16 | $31.16M derived: sum of 3 quarters · filed 2020-03-16 | $41.41M 10-K · filed 2020-03-16 |
| 2017-09-30 | $10.13M 10-K · filed 2020-03-16 | $20.95M derived: sum of 2 quarters · filed 2020-03-16 | $31.21M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $10.83M 10-K · filed 2020-03-16 | $21.09M derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-03-31 | $10.26M 10-K · filed 2020-03-16 | |||
| 2016-12-31 | $39.30M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |